UGT1A1 inactivates bilirubin and metabolizes irinotecan (a cancer drug). Variants affect jaundice risk and chemotherapy toxicity.
Intermediate/Poor Metabolizer
Drug
Irinotecan
Effect
Reduced glucuronidation → increased SN-38 → severe toxicity
Recommendation
ADJUST. Consider 25-30% dose reduction.
CPIC Guideline
CPIC Level A
FDA Label
FDA recommends dose adjustment based on UGT1A1
Clinical Action: These recommendations are based on CPIC guidelines and FDA labeling. Discuss results with your healthcare provider or genetic counselor to determine appropriate treatment adjustments.
Know your UGT1A1 status? Get a personalized medication safety report.
Generate My Report